Skip to content
  • BiotechReality JobFinder
  • Market Analysis
  • Publish on BiotechReality
  • linkedin
  • facebook
  • instagram
  • twitter
BiotechReality Home
BiotechReality – Information Intelligence System for Biopharma
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
Popular
#FDA #Eli Lilly and Company #Johnson&Johnson #Clinical Data #FDA Approval #Cancer #Phase 3 Trials #Novo Nordisk

Ajmal Aseem

Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
Clinical Trials Healthcare & Pharmaceuticals News

Amgen’s IMDELLTRA® Phase 3 Trials Demonstrated Superior Overall Survival in Small Cell Lung Cancer

  • By Ajmal Aseem
  • 12 April 2025
amgen

IMDELLTRA’s safety profile was consistent with the recognized profile. Detailed DeLLphi-304 results will be presented at an upcoming medical congress.

Tagged Amgen, IMDELLTRA®, Small Cell Lung Cancer
Regulatory Healthcare & Pharmaceuticals News

U.S. FDA to Phase Out Animal Testing for the Development of Monoclonal Antibodies and Other Drugs

  • By Ajmal Aseem
  • 11 April 2025
US FDA News

The FDA’s animal testing requirement will be decreased, modified, or potentially replaced utilizing a variety of methodologies.

Tagged Animal Testing, Drug Development, FDA, Monoclonal Antibodies
Science Life Sciences News

Dire Wolf Returns After 12000 Years By De-Extinction Technology

  • By Ajmal Aseem
  • 9 April 2025
dire wolf

Colossal Biosciences, the business seeking to make extinction optional, has resurrected a prehistoric predator best known for its role in Game of Thrones. Approximately 20 [Read More…]

Tagged De-Extinction, Dire Wolf
Business Healthcare & Pharmaceuticals News

mAb Capture Made Cost Effective and Productive With Cytiva’s Protein A Resins

  • By Ajmal Aseem
  • 8 April 2025
cytiva resins

A one-size-fits-all strategy to protein purification is no longer practicable, given the development and transformation of the mAb market, notably the recent rapid emergence of [Read More…]

Tagged Cytiva, Monoclonal Antibodies, Protein A Resins
Research Vaccines

New Vaccination Concept Targets Dangerous Bacteria in the Intestine

  • By Ajmal Aseem
  • 4 April 2025
new vaccination concept

For a long time, scientists have been looking into vaccines against pathogenic bacteria in the bowel, particularly those that drugs have proved ineffective against due to resistance.

Tagged Bacteria, Vaccination
Regulatory Business Healthcare & Pharmaceuticals News

Aldeyra Therapeutics Responds to the U.S. FDA’s Denial of Reproxalap’s NDA Application for Treating Signs and Symptoms of Dry Eye Disease

  • By Ajmal Aseem
  • 3 April 2025
US FDA News

FDA stated in the letter that the NDA “failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes”.

Tagged Aldeyra Therapeutics, FDA, Reproxalap
Regulatory Approval Business Healthcare & Pharmaceuticals News

Pfizer’s RSV Lower Respiratory Tract Disease Vaccine ABRYSVO®Approved by European Commission

  • By Ajmal Aseem
  • 1 April 2025
pfizer news

Pfizer Inc (PFI). announced that the European Commission (EC) has amended the marketing authorization for ABRYSVO®, the company’s bivalent respiratory syncytial virus (RSV) prefusion F [Read More…]

Tagged ABRYSVO, Pfizer, RSV
Regulatory Approval Business Healthcare & Pharmaceuticals News

U.S. FDA Approved Sanofi’s Qfitlia to Treat Hemophilia

  • By Ajmal Aseem
  • 30 March 2025
sanofi

In order to help hemophiliacs regain hemostasis, Qfitlia helps boost thrombin production by decreasing AT, a protein that prevents blood clotting.

Tagged FDA, FDA Approval, Qfitlia, Sanofi
Business Clinical Trials Healthcare & Pharmaceuticals News

Bayer and Puhe BioPharma With Global License Agreement For Clinical Phase I PRMT5 Inhibitor for Brain Tumors

  • By Ajmal Aseem
  • 26 March 2025
The Bayer Cross in Leverkusen

For the clinical phase, Bayer has acquired the sole global license for an MTA-cooperative PRMT5 inhibitor that targets MTAP-deleted tumors selectively.

Tagged Bayer, Phase 1 Clinical Trials, PRMT5 Inhibitor
Clinical Trials Neuroscience Research

Newly Developed Anti-amyloid Drug Shows Positive Signs of Preventing Alzheimer’s Dementia

  • By Ajmal Aseem
  • 23 March 2025
anti amyloid clinical trial alzheimer's drug

Eliminating amyloid from the brain may prevent symptoms in those who are destined to acquire early-onset Alzheimer’s disease, according to a clinical experiment. This suggests the need for additional research.

Tagged Alzheimer's, Dementia, Investigational Drug

Posts navigation

← Older Posts
→ Newer Posts
Advertisement

Areas Covered

  • Anti-obesity Drugs
  • Artificial Intelligence
  • Astrobiology
  • Autoimmune Diseases
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biologics
  • Biosimilars
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • CDMO
  • Cell Biology
  • Clinical Data
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • CRDMO
  • CRO
  • Cybersecurity
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Legal and Patent Affairs
  • Life Sciences
  • Machine Learning
  • Manufacturing
  • Medical Devices
  • Mental Health
  • Merger & Acquisitions
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Oncology
  • Pharmacology
  • Rare Diseases
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Supply Chain
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs

Discover More

MSD Oncology Pipeline Advances With First Phase 3 Data for Intismeran Autogene Plus KEYTRUDA and Sacituzumab Tirumotecan
Clinical Data Healthcare & Pharmaceuticals News Oncology

MSD Oncology Pipeline Advances With First Phase 3 Data for Intismeran Autogene Plus KEYTRUDA and Sacituzumab Tirumotecan

17 October 202617 October 2026
Ajmal Aseem
Regeneron Libtayo Dosing Update: CHMP Recommends EU Approval of Every-Six-Week Cemiplimab Regimen Across All Cancer Types
Regulatory Approval Healthcare & Pharmaceuticals News Oncology

Regeneron Libtayo Dosing Update: CHMP Recommends EU Approval of Every-Six-Week Cemiplimab Regimen Across All Cancer Types

16 October 202617 October 2026
Ajmal Aseem
Lilly Omvoh (mirikizumab-mrkz) Delivers Comprehensive Disease Control in Ulcerative Colitis and Deep Remission in Crohn’s Disease at One Year
Clinical Data Healthcare & Pharmaceuticals News

Lilly Omvoh (mirikizumab-mrkz) Delivers Comprehensive Disease Control in Ulcerative Colitis and Deep Remission in Crohn’s Disease at One Year

15 October 202615 October 2026
Ajmal Aseem
Charles River Magellan Collaboration Backs Zelestrocel Osteoarthritis Therapy With cGMP NGS Viral Safety Testing
Business Clinical Data Gene Therapy Healthcare & Pharmaceuticals News

Charles River Magellan Collaboration Backs Zelestrocel Osteoarthritis Therapy With cGMP NGS Viral Safety Testing

14 October 202614 October 2026
Ajmal Aseem
Johnson & Johnson Q3 2026 Results: J&J Raises 2026 Guidance as OTTAVA, IMAAVY and RYBREVANT FASPRO Advance
Business Healthcare & Pharmaceuticals News

Johnson & Johnson Q3 2026 Results: J&J Raises 2026 Guidance as OTTAVA, IMAAVY and RYBREVANT FASPRO Advance

13 October 202614 October 2026
Ajmal Aseem
IQVIA Veeva Clinical Operations Expansion: IQVIA Selects Veeva CTMS, eTMF, Study Startup and Site Connect as Enterprise Standards
Business Artificial Intelligence Clinical Data Healthcare & Pharmaceuticals News Research

IQVIA Veeva Clinical Operations Expansion: IQVIA Selects Veeva CTMS, eTMF, Study Startup and Site Connect as Enterprise Standards

13 October 202613 October 2026
Ajmal Aseem
Advertisement
BiotechReality JobFinder

  • Clinical Project Management Director – IQVIA
    16 October 2026
  • Senior Manager, Global Digital Marketing – Lonza
    11 October 2026
  • Commercial Product Manager – Centrifuge – ThermoFisher, Singapore & Malaysia
    7 October 2026
  • Regulatory Affairs Specialist – Lonza, Hyderabad
    4 October 2026
  • Component Engineer – Cytiva, Bangalore
    29 September 2026

BiotechReality Shots Weekly Newsletter

Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
SciRealityPress BiotechReality

A SciRealityPress Associate

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2026
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
  • linkedin
  • facebook
  • instagram
  • twitter